propranolol has been researched along with Allodynia in 16 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Resveratrol significantly decreased thermal allodynia (and not anxiety) in all experimental days." | 4.02 | Intracerebroventricular injection of propranolol blocked analgesic and neuroprotective effects of resveratrol following L ( Bahari, Z; Bahrami, F; Ghasemi, M; Hosseini, M; Iman, M; Mohammadi, MT; Zabihian, MA, 2021) |
| " Results VL-102-evoked acute and chronic mechanical cephalic and hind-paw allodynia in a dose-dependent manner, which was blocked by the migraine medications sumatriptan, propranolol, and topiramate." | 3.88 | Soluble guanylyl cyclase is a critical regulator of migraine-associated pain. ( Ben Aissa, M; Bennett, BM; Bertels, Z; Gaisina, IN; Gandhi, R; Lee, SH; Litosh, V; Moye, LS; Novack, M; Pradhan, AA; Thatcher, GR; Tipton, AF; Wang, Y, 2018) |
| "A genetic analysis of opioid-induced hyperalgesia in mice linked the β(2)-adrenergic receptor to mechanical sensitization after opioid exposure." | 2.77 | Modulation of remifentanil-induced postinfusion hyperalgesia by the β-blocker propranolol in humans. ( Angst, MS; Chu, LF; Clark, DJ; Cun, T; Kim, JE; Ngai, LK; Young, CA; Zamora, AK, 2012) |
| "Pretreatment with propranolol or nor-BNI prior to restraint stress prevented both transient cutaneous allodynia and priming, demonstrated by a lack of umbellulone-induced cutaneous allodynia." | 1.62 | A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain. ( Chessell, IP; Dodick, DW; Kopruszinski, CM; Navratilova, E; Porreca, F; Swiokla, J, 2021) |
| "Therapeutic potential of agomelatine on neuropathic pain was suppressed with α-methyl-para-tyrosine methyl ester (an inhibitor of catecholamine synthesis), phentolamine (a nonselective α-adrenoceptor antagonist), and propranolol (a nonselective β-adrenoceptor antagonist) administrations." | 1.43 | Effect of subacute agomelatine treatment on painful diabetic neuropathy: involvement of catecholaminergic mechanisms. ( Aydın, TH; Can, ÖD; Demir Özkay, Ü; Turan, N, 2016) |
| "injection abolished carrageenan-evoked hyperalgesia at the doses, at which the drugs failed to alter the hypersensitivity when they were given alone." | 1.39 | Effects of a combination of ketanserin and propranolol on inflammatory hyperalgesia in rats. ( Hong, Y; Wang, D; Zhou, X, 2013) |
| " In vagotomized rats, chronic administration of ICI 118,551 markedly attenuated vagotomy-induced enhancement of bradykinin hyperalgesia but had no effect on nociceptive threshold." | 1.32 | Vagal modulation of nociception is mediated by adrenomedullary epinephrine in the rat. ( Green, PG; Khasar, SG; Levine, JD; Miao, FJ, 2003) |
| "Mechanical hyperalgesia, however, was less sensitive to inhibition by propranolol and guanethedine but significantly inhibited by phentolamine." | 1.31 | The role of the sympathetic efferents in endotoxin-induced localized inflammatory hyperalgesia and cytokine upregulation. ( Haddad, JJ; Jabbur, SJ; Massaad, CA; Poole, S; Saadé, NE; Safieh-Garabedian, B, 2002) |
| "Bradykinin-induced hyperalgesia was abolished by HOE 140 and by treatment of the paws with anti-TNF-alpha antisera." | 1.29 | Bradykinin release of TNF-alpha plays a key role in the development of inflammatory hyperalgesia. ( Cunha, FQ; Ferreira, SH; Lorenzetti, BB; Poole, S, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 10 (62.50) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kopruszinski, CM | 1 |
| Navratilova, E | 1 |
| Swiokla, J | 1 |
| Dodick, DW | 1 |
| Chessell, IP | 1 |
| Porreca, F | 1 |
| Zabihian, MA | 1 |
| Hosseini, M | 1 |
| Bahrami, F | 1 |
| Iman, M | 1 |
| Ghasemi, M | 1 |
| Mohammadi, MT | 1 |
| Bahari, Z | 1 |
| Boyer, N | 1 |
| Signoret-Genest, J | 1 |
| Artola, A | 1 |
| Dallel, R | 1 |
| Monconduit, L | 1 |
| Ben Aissa, M | 1 |
| Tipton, AF | 1 |
| Bertels, Z | 1 |
| Gandhi, R | 1 |
| Moye, LS | 1 |
| Novack, M | 1 |
| Bennett, BM | 1 |
| Wang, Y | 1 |
| Litosh, V | 1 |
| Lee, SH | 1 |
| Gaisina, IN | 1 |
| Thatcher, GR | 1 |
| Pradhan, AA | 1 |
| Romero, TRL | 1 |
| Soares Santos, RR | 1 |
| Castor, MGME | 1 |
| Petrocchi, JA | 1 |
| Guzzo, LS | 1 |
| Klein, A | 1 |
| Duarte, IDG | 1 |
| Wang, D | 1 |
| Zhou, X | 1 |
| Hong, Y | 1 |
| Park, PE | 1 |
| Schlosburg, JE | 1 |
| Vendruscolo, LF | 1 |
| Schulteis, G | 1 |
| Edwards, S | 1 |
| Koob, GF | 1 |
| Aydın, TH | 1 |
| Can, ÖD | 1 |
| Demir Özkay, Ü | 1 |
| Turan, N | 1 |
| Long, Q | 1 |
| Liu, X | 1 |
| Qi, Q | 1 |
| Guo, SW | 1 |
| Chu, LF | 1 |
| Cun, T | 1 |
| Ngai, LK | 1 |
| Kim, JE | 1 |
| Zamora, AK | 1 |
| Young, CA | 1 |
| Angst, MS | 1 |
| Clark, DJ | 1 |
| Werner, MU | 1 |
| Barchini, J | 1 |
| Tchachaghian, S | 1 |
| Shamaa, F | 1 |
| Jabbur, SJ | 2 |
| Meyerson, BA | 1 |
| Song, Z | 1 |
| Linderoth, B | 1 |
| Saadé, NE | 2 |
| Khasar, SG | 1 |
| Green, PG | 1 |
| Miao, FJ | 1 |
| Levine, JD | 1 |
| Ferreira, SH | 1 |
| Lorenzetti, BB | 1 |
| Cunha, FQ | 1 |
| Poole, S | 2 |
| Ernberg, M | 1 |
| Lundeberg, T | 1 |
| Kopp, S | 1 |
| Safieh-Garabedian, B | 1 |
| Haddad, JJ | 1 |
| Massaad, CA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Beta Blockade on Opioid-Induced Hyperalgesia in Humans[NCT01222091] | Phase 2 | 10 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| The Serotonin Receptor Type 3 Antagonist Granisetron as a New Treatment Approach for Patients With Chronic Myofascial Pain in the Orofacial Muscles[NCT02230371] | Phase 4 | 40 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
OOWS: Is a 13-item instrument of documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. Maximum score = 13, minimum score = 0. Lower scores correspond to fewer symptoms. (NCT01222091)
Timeframe: Pretreatment [90 min prior to 60-min REM infusion]; 30 min prior to 60-min REM infusion; 15 and 40 min after start of 60-min REM infusion; 5, 15, and 75 minutes after finish of 60-min REM infusion)
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Pretreatment | 30 min prior to REM infusion | 15 min after start of REM infusion | 40 min after start of REM infusion | 5 minutes after finish of REM infusion | 15 minutes after finish of REM infusion | 75 minutes after finish of REM infusion | |
| Placebo | 1.1 | 1.1 | 0.8 | 0.5 | 1.8 | 2.1 | 1.6 |
| Propranolol | 1.2 | 1.1 | 0.1 | 0.8 | 3 | 2.8 | 1.7 |
A slightly modified version of a previously described model of secondary hyperalgesia was used. Two copper wires contained in a microdialysis catheter were inserted in parallel over a length of 5 mm into the dermis of the right volar forearm. The wires were connected to a constant current stimulator controlled by a pulse generator to deliver rectangular and monophasic pulses with a duration of 0.5 mg at 2 Hz. Over a period of 15 min, the current was increased by targeting a pain rating of 5 on an 11-point numeric rating scale (0 = no pain and 10 = maximum tolerable pain) until the hyperalgesic area surrounding the stimulation site was fully established. Once the area was established, the current was held constant. Percent change from baseline in size (area) of secondary hyperalgesia after cessation of remifentanil infusion was calculated per group. (NCT01222091)
Timeframe: Baseline; 15 min post remifentanil (REM) infusion; 60 min post REM infusion
| Intervention | percentage of change (Number) | |
|---|---|---|
| 15 min post remifentanil infusion | 60 min post remifentanil infusion | |
| Placebo | -34 | 141.5 |
| Propranolol | -28 | -19 |
2 trials available for propranolol and Allodynia
| Article | Year |
|---|---|
Modulation of remifentanil-induced postinfusion hyperalgesia by the β-blocker propranolol in humans.
Topics: Adolescent; Adult; Analgesics; Cross-Over Studies; Double-Blind Method; Humans; Hyperalgesia; Male; | 2012 |
Effect of propranolol and granisetron on experimentally induced pain and allodynia/hyperalgesia by intramuscular injection of serotonin into the human masseter muscle.
Topics: Adult; Double-Blind Method; Drug Combinations; Female; Granisetron; Humans; Hyperalgesia; Injections | 2000 |
14 other studies available for propranolol and Allodynia
| Article | Year |
|---|---|
A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain.
Topics: Animals; Calcitonin Gene-Related Peptide; Disease Models, Animal; Female; Hyperalgesia; Male; Mice; | 2021 |
Intracerebroventricular injection of propranolol blocked analgesic and neuroprotective effects of resveratrol following L
Topics: Analgesics; Animals; Disease Models, Animal; Hyperalgesia; Ligation; Male; Neuroprotective Agents; P | 2021 |
Propranolol treatment prevents chronic central sensitization induced by repeated dural stimulation.
Topics: Adrenergic beta-Antagonists; Afferent Pathways; Animals; Central Nervous System Sensitization; Chlor | 2017 |
Soluble guanylyl cyclase is a critical regulator of migraine-associated pain.
Topics: Adrenergic beta-Antagonists; Allosteric Regulation; Animals; Anticonvulsants; Calcitonin Gene-Relate | 2018 |
Noradrenaline induces peripheral antinociception by endogenous opioid release.
Topics: Analgesics; Animals; Cinnamates; Dinoprostone; Dose-Response Relationship, Drug; Hyperalgesia; Leuci | 2018 |
Effects of a combination of ketanserin and propranolol on inflammatory hyperalgesia in rats.
Topics: Analgesics; Animals; Arthritis; Carrageenan; Dose-Response Relationship, Drug; Drug Interactions; Hy | 2013 |
Chronic CRF1 receptor blockade reduces heroin intake escalation and dependence-induced hyperalgesia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antag | 2015 |
Effect of subacute agomelatine treatment on painful diabetic neuropathy: involvement of catecholaminergic mechanisms.
Topics: Acetamides; Animals; Blood Glucose; Catecholamines; Diabetes Mellitus, Experimental; Diabetic Neurop | 2016 |
Chronic stress accelerates the development of endometriosis in mouse through adrenergic receptor β2.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals | 2016 |
Vanguard research in opioid-induced hyperalgesia - but guard the basics.
Topics: Analgesics; Humans; Hyperalgesia; Male; Piperidines; Propranolol; Remifentanil | 2012 |
Spinal segmental and supraspinal mechanisms underlying the pain-relieving effects of spinal cord stimulation: an experimental study in a rat model of neuropathy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Analysis of Variance; Animals; Baclofen; | 2012 |
Vagal modulation of nociception is mediated by adrenomedullary epinephrine in the rat.
Topics: Adrenal Medulla; Adrenergic beta-Antagonists; Animals; Behavior, Animal; Bradykinin; Dose-Response R | 2003 |
Bradykinin release of TNF-alpha plays a key role in the development of inflammatory hyperalgesia.
Topics: Animals; Bradykinin; Dose-Response Relationship, Drug; Hindlimb; Hyperalgesia; Indomethacin; Inflamm | 1993 |
The role of the sympathetic efferents in endotoxin-induced localized inflammatory hyperalgesia and cytokine upregulation.
Topics: Adrenergic alpha-Antagonists; Adrenergic Antagonists; Adrenergic Fibers; Animals; Cytokines; Dose-Re | 2002 |